Fig. 1 | Signal Transduction and Targeted Therapy

Fig. 1

From: Dynamic transcriptional immune landscape in response to NK-cell therapy combined with gemcitabine plus S-1 in advanced pancreatic cancer: a phase 1b/2 trial

Fig. 1

Study procedure schema and Consolidated Standards of Reporting Trials (CONSORT) diagram. a Clinical trial schema for screening, apheresis, NK cell manufacturing, treatment with chemotherapy combined with NK cell infusion, and follow-up. b Flowchart of the detailed clinical treatment protocol. Each treatment cycle included standard GS chemotherapy from days 1 to 14, followed by allogeneic NK cell administration from days 14 to 21 (a single infusion per cycle for doses of 1 × 109 cells, 2 × 109 cells, and 4 × 109 cells, or half of the dose fractionated over two consecutive days for a dose of 8 × 109 cells). c CONSORT flow diagram indicating the number of patients enrolled, who received treatments, and who were included in the analysis. G gemcitabine, GS gemcitabine plus S-1, V visit, CT computed tomography

Back to article page